Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Cardiology · Heart Failure

Why Monitor Kidney Function and Potassium in Heart Failure?

At a Glance

Kidney function and potassium are monitored during heart failure treatment because ACE inhibitors, ARBs, ARNIs, MRAs, and diuretics can change kidney filtration and potassium levels. Regular blood tests help clinicians adjust doses safely; an abnormal result does not always mean kidney damage.

Heart failure medications are a combination of therapies that relieve fluid overload, reduce strain on the heart, and improve long-term outcomes [1]. However, we monitor your blood work closely because these same medicines change how your kidneys filter blood and handle essential electrolytes like potassium and sodium. Regular blood tests help detect changes early, ensuring that your treatment is adjusted safely without causing severe chemical imbalances.

An abnormal lab result does not automatically mean your kidneys are permanently damaged or that the treatment has failed; testing is simply a routine tool to help your doctor find the right dose for your body.

How Your Medications Change Kidney Function and Potassium

Heart failure treatment often involves multiple medications that interact with your kidneys in different ways. Your doctor monitors your creatinine (a blood marker used to estimate your overall kidney filtration rate, known as eGFR) and electrolytes like potassium.

  • ACE Inhibitors, ARBs, and ARNIs: Medications like lisinopril, losartan, or sacubitril/valsartan relax blood vessels to lower blood pressure and take stress off the heart [2]. While doing this, they change the blood flow inside your kidneys. A modest increase in your creatinine level is a common, expected effect [3]. However, they also cause your body to retain potassium [4]. (Note: ACE inhibitors, ARBs, and ARNIs are alternatives to each other. They should never be taken together, and switching between them requires specific instructions from your doctor).
  • Mineralocorticoid Receptor Antagonists (MRAs): Drugs like spironolactone and eplerenone are powerful tools for improving survival, but they specifically cause your kidneys to hold on to potassium [5]. Combining them with an ACE inhibitor, ARB, or ARNI further increases the risk of high potassium (hyperkalemia) [6].
  • Diuretics (Water Pills): Loop diuretics like furosemide or torsemide force your kidneys to flush out excess fluid and sodium [7]. As fluid is removed, you also lose potassium and magnesium in your urine, which can lead to low levels [8]. If diuretics remove fluid too quickly, it can lead to dehydration and stress the kidneys, causing your creatinine to rise [9].
Medication Class Example Drugs Common Effect on Potassium Typical Monitoring Focus
ACE Inhibitors / ARBs / ARNIs Lisinopril, Losartan, Entresto May increase potassium eGFR, creatinine, potassium within 1-2 weeks of starting or changing dose [3]
MRAs Spironolactone, Eplerenone May increase potassium eGFR, potassium (often within 3-7 days of starting or changing dose) [3]
Loop Diuretics Furosemide, Torsemide May decrease potassium Kidney function, sodium, potassium, magnesium, and fluid status [7]

The Testing Schedule: What to Expect

Because underlying kidney disease or abnormal potassium levels can alter the safety of your medications, your care team relies on a structured testing approach:

  • Baseline Testing: Before starting a new medication, your doctor checks your baseline eGFR and potassium to ensure it is safe [10]. For example, MRAs usually require an eGFR above 30 and potassium below 5.0 mEq/L before starting [5].
  • Follow-Up Testing: You will need repeat blood work shortly after starting a drug or changing a dose. The exact timing depends on the drug, your kidney function, and your individual risk. MRA monitoring may occur within 3 days to 1 week, while ACE inhibitors might be checked in 1 to 2 weeks [3]. Always get your blood drawn on the exact date your care team provides.
  • Routine Surveillance: Once on a stable dose, you will still need regular monitoring [11].

What Happens If Your Results Are Abnormal?

Your doctor is looking for trends in your lab work to guide your care. They balance the need to protect your kidneys with keeping your heart failure treated.

  • Changes prompt assessment, not automatic stops: A temporary increase in creatinine during successful fluid removal doesn’t necessarily mean permanent kidney injury [12]. Even a creatinine rise of up to 30% when starting an ACE inhibitor, ARB, or ARNI can be an acceptable response [3]. These numbers are decision points for your doctor to assess your fluid status and blood pressure, not universal rules to stop treatment [13].
  • When action is needed: If your creatinine rises sharply or your potassium levels reach certain thresholds (like 5.5 mEq/L or higher), your doctor will take action [14]. They may adjust a dose, temporarily pause the drug, prescribe a medication to help remove excess potassium, or refer you to a kidney specialist [15][16]. Never stop or adjust your heart failure medications on your own based on a lab result.

Warning Signs and Everyday Safety

  • Watch for Emergency Symptoms: High potassium often has no symptoms at all. However, if you experience new palpitations, severe weakness, fainting, or chest pain, seek emergency medical care immediately. If you have severe dizziness or drastically reduced urination, contact your care team promptly.
  • Avoid Hidden Potassium and Kidney Stressors: Because of the risk of hyperkalemia, never take over-the-counter potassium supplements or use potassium-based salt substitutes (often marketed as “low sodium” salt) unless explicitly prescribed [17][18].
  • Beware of NSAIDs and Sick Days: Over-the-counter pain relievers like ibuprofen and naproxen (NSAIDs) can severely stress your kidneys and worsen heart failure [19]. Additionally, vomiting, diarrhea, or poor fluid intake can lead to dangerous dehydration. Always ask your care team for guidance on “sick day” rules rather than stopping medications yourself [3].

Common questions in this guide

Why are kidney function and potassium checked when I take heart failure medicine?
Many heart failure medicines change how the kidneys filter blood, remove fluid, or retain potassium. Blood tests measure creatinine, a marker of kidney filtering, and potassium so the care team can adjust treatment before a serious imbalance develops. An abnormal result does not automatically mean permanent kidney damage.
Which heart failure medicines can make potassium too high or too low?
ACE inhibitors, ARBs, ARNIs, and MRAs can make potassium rise because the body holds on to more potassium. Loop diuretics can make potassium fall because they increase potassium loss in urine. ACE inhibitors, ARBs, and ARNIs are alternatives and should not be combined unless your clinician gives specific instructions.
Is a rise in creatinine after starting heart failure medicine always dangerous?
No. A modest rise in creatinine can occur when some heart failure medicines are started or when excess fluid is removed, and it does not automatically mean permanent kidney injury. Your clinician will consider the amount and trend of the change along with your blood pressure and fluid status; a sharp rise needs prompt assessment.
When will I need blood tests after starting or changing a heart failure medicine?
Testing is usually done before treatment to establish kidney function and potassium levels, then repeated after a medicine is started or its dose changes. Monitoring for an MRA may occur within about 3 days to 1 week, while ACE inhibitors, ARBs, or ARNIs may be checked within 1 to 2 weeks. The exact schedule depends on the medicine, your kidney function, and your care team's instructions.
What should I avoid while my potassium and kidney function are being monitored?
Do not use potassium supplements or potassium-based salt substitutes unless your care team specifically prescribes them. Ask before taking NSAID pain relievers such as ibuprofen or naproxen because they can stress the kidneys and worsen heart failure. If vomiting, diarrhea, or poor fluid intake occurs, ask about your sick-day instructions instead of stopping medicines on your own.
What symptoms need urgent help during heart failure medicine monitoring?
High potassium often causes no symptoms, but new palpitations, severe weakness, fainting, or chest pain require emergency medical care. Severe dizziness or a major reduction in urination should prompt a call to your care team. Do not wait for symptoms to schedule blood tests.

Get notified when new evidence is published on congestive heart failure.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Identifying the patient with heart failure to be treated with vericiguat.

    Escobar Cervantes C, Esteban Fernández A, Recio Mayoral A, et al.

    Current medical research and opinion 2023; (39(5)):661-669 doi:10.1080/03007995.2023.2189857.

    PMID: 36897009
  2. 2

    Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.

    Liu RC

    American journal of cardiovascular drugs : drugs, devices, and other interventions 2018; (18(6)):473-482 doi:10.1007/s40256-018-0280-5.

    PMID: 29850980
  3. 3

    Change in renal function associated with drug treatment in heart failure: national guidance.

    Clark AL, Kalra PR, Petrie MC, et al.

    Heart (British Cardiac Society) 2019; (105(12)):904-910 doi:10.1136/heartjnl-2018-314158.

    PMID: 31118203
  4. 4

    Treatment of Hyperkalemia in Heart Failure.

    DeFilippis EM, Desai AS

    Current heart failure reports 2017; (14(4)):266-274 doi:10.1007/s11897-017-0341-0.

    PMID: 28656517
  5. 5

    Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review.

    Mares A, Rodriguez T, Deoker A, et al.

    Current vascular pharmacology 2022; (20(1)):46-51 doi:10.2174/1570161119666210720120439.

    PMID: 34303331
  6. 6

    Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.

    Desai AS, Vardeny O, Claggett B, et al.

    JAMA cardiology 2017; (2(1)):79-85 doi:10.1001/jamacardio.2016.4733.

    PMID: 27842179
  7. 7

    Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis.

    Brisco-Bacik MA, Ter Maaten JM, Houser SR, et al.

    Journal of the American Heart Association 2018; (7(18)):e009149 doi:10.1161/JAHA.118.009149.

    PMID: 30371181
  8. 8

    Hyponatremia in acute decompensated heart failure: depletion versus dilution.

    Verbrugge FH, Steels P, Grieten L, et al.

    Journal of the American College of Cardiology 2015; (65(5)):480-92.

    PMID: 25660927
  9. 9

    Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians.

    Wu L, Rodriguez M, El Hachem K, Krittanawong C

    Journal of clinical medicine 2024; (13(15)) doi:10.3390/jcm13154470.

    PMID: 39124738
  10. 10

    Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.

    Parikh RV, Nash DM, Brimble KS, et al.

    Circulation. Cardiovascular quality and outcomes 2020; (13(9)):e006415 doi:10.1161/CIRCOUTCOMES.119.006415.

    PMID: 32873054
  11. 11

    New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.

    Tamargo J, Caballero R, Delpón E

    Cardiovascular drugs and therapy 2018; (32(1)):99-119 doi:10.1007/s10557-017-6767-5.

    PMID: 29372448
  12. 12

    Acute kidney injury in acute heart failure-when to worry and when not to worry?

    Banerjee D, Ali MA, Wang AY, Jha V

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (40(1)):10-18 doi:10.1093/ndt/gfae146.

    PMID: 38944413
  13. 13

    Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus.

    Collard D, Brouwer TF, Peters RJG, et al.

    Hypertension (Dallas, Tex. : 1979) 2018; (72(6)):1337-1344 doi:10.1161/HYPERTENSIONAHA.118.11944.

    PMID: 30571235
  14. 14

    Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.

    Flatt DM, Brown MC, Mizeracki AM, et al.

    JAMA cardiology 2016; (1(5)):607-12 doi:10.1001/jamacardio.2016.1878.

    PMID: 27434136
  15. 15

    Chronic hyperkalemia, diagnosis and management. Colombian consensus.

    Rico-Fontalvo J, Rodríguez-González MJ, Yama EY, et al.

    Archivos de cardiologia de Mexico 2023; (93(Supl)):1-12 doi:10.24875/ACM.23000160.

    PMID: 37913795
  16. 16

    Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use.

    Clark KAA, Victoria-Castro AM, Ghazi L, et al.

    JACC. Heart failure 2024; (12(2)):322-332 doi:10.1016/j.jchf.2023.08.025.

    PMID: 37943221
  17. 17

    New options for the management of chronic hyperkalemia.

    Fried L, Kovesdy CP, Palmer BF

    Kidney international supplements 2017; (7(3)):164-170 doi:10.1016/j.kisu.2017.09.001.

    PMID: 30675431
  18. 18

    Management of Hyperkalemia in Heart Failure.

    Altay H, Çavuşoğlu Y, Çelik A, et al.

    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2021; (49(Supp1)):1-32 doi:10.5543/tkda.2021.S1.

    PMID: 34738907
  19. 19

    Community prescribing of potentially nephrotoxic drugs and risk of acute kidney injury requiring renal replacement therapy in critically ill adults: A national cohort study.

    Tominey S, Timmins A, Lee R, et al.

    Journal of the Intensive Care Society 2021; (22(2)):102-110 doi:10.1177/1751143719900099.

    PMID: 34025749

This page explains why kidney function and potassium are monitored during heart failure treatment for informational purposes only and does not constitute medical advice. Your heart failure team should interpret your results and advise you about medicines, diet, and illness-related changes.